Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gender Discrimination Trial Begins; Company Consultant Found Problems in 2003

This article was originally published in The Pink Sheet Daily

Executive Summary

Women sales reps claim Novartis discriminates in pay and promotion; Novartis attorney says company implemented consultant's recommendations and has made progress in promoting women.

You may also be interested in...



Successful Novartis Sales Reps' Performance Scores Could Be Downgraded To Satisfy Budget Goals, Gender Discrimination Trial Reveals

Former head of human resources testifies at gender discrimination trial that 12 percent of a given employee population had to receive low performance ratings.

Successful Novartis Sales Reps' Performance Scores Could Be Downgraded To Satisfy Budget Goals, Gender Discrimination Trial Reveals

Former head of human resources testifies at gender discrimination trial that 12 percent of a given employee population had to receive low performance ratings.

Legal Briefs: AstraZeneca Wins Seroquel Suit, King Settles With DoJ, Sanofi Resolves Gender Discrimination Suit

AstraZeneca wins first Seroquel product liability trial: A New Jersey state court jury reached a verdict in favor of AstraZeneca, rejecting a plaintiff's claims that the antipsychotic caused his diabetes. The case, Baker v. AstraZeneca, is the first to go to trial. AstraZeneca is facing more than 14,000 Seroquel (quetiapine) lawsuits involving more than 22,000 plaintiffs alleging the company failed to adequately warn of the risk of diabetes. Nine previous cases set for trial were dismissed. The company said that in these cases and in the Baker suit, the facts showed that the plaintiffs either already had diabetes or had so many pre-existing risk factors that they had a significantly increased risk of diabetes before taking Seroquel

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel